Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.9 USD | +0.71% |
|
+2.12% | -35.44% |
06-24 | JPMorgan Cuts Price Target on Cytokinetics to $65 From $77, Maintains Overweight Rating | MT |
06-17 | Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing | MT |
Evolution of the average Target Price on Cytokinetics, Incorporated
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
![Consensus](/images/consensus_flch.gif)
Consensus detail
Consensus revision (last 18 months)
Analysts covering Cytokinetics, Incorporated
B. Riley | |
Truist Securities | |
JMP Securities | |
Raymond James | |
Needham & Co. | |
Oppenheimer | |
Mizuho Securities | |
UBS | |
Cantor Fitzgerald | |
HC Wainwright | |
Goldman Sachs | |
SVB Securities LLC | |
JPMorgan Chase | |
BofA Securities | |
Morgan Stanley | |
Piper Sandler | |
Jefferies & Co. | |
Barclays | |
Wolfe Research |
EPS Revisions
- Stock Market
- Equities
- CYTK Stock
- Consensus Cytokinetics, Incorporated